1 active not recruiting, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow ABBV-744: new trials by email Literature Review of ABBV-744 trials Research Report on ABBV-744
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis ABBV-744, Navitoclax, Ruxolitinib - Myelofibrosis (MF) | Phase 1 | Active not recruiting | AbbVie | 21 | 2020-11-11 | 2025-07-16 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer ABBV-744 - Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | AbbVie | 30 | 2018-03-16 | 2021-03-24 |
Leukemia, Myeloid, Acute (1) · Neoplasms (1) · Primary Myelofibrosis (1)
AbbVie (2)
United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1)